{"id":174,"date":"2017-05-18T17:28:31","date_gmt":"2017-05-18T15:28:31","guid":{"rendered":"http:\/\/www.austrian-apheresis-association.at\/aaa\/?page_id=174"},"modified":"2017-10-10T13:19:37","modified_gmt":"2017-10-10T11:19:37","slug":"oegim-2014","status":"publish","type":"page","link":"https:\/\/www.austrian-apheresis-association.at\/aaa\/en\/oegim-2014\/","title":{"rendered":"\u00d6GIM 2014"},"content":{"rendered":"<p><\/p>\n<p class=\"rtecenter\">25 &#8211; 27 September, 2014<\/p>\n<p class=\"rtecenter\">Salzburg Congress, Austria<\/p>\n<p class=\"rtecenter\"><a href=\"https:\/\/www.austrian-apheresis-association.at\/aaa\/wp-content\/uploads\/2017\/06\/Oegim_Program_2014.pdf\" class=\"pdfemb-viewer\" style=\"\" data-width=\"max\" data-height=\"max\" data-toolbar=\"bottom\" data-toolbar-fixed=\"off\">\u00d6GIM 2015<\/a><\/p>\n<p>&nbsp;<\/p>\n<hr \/>\n<div><b><i>Lipoprotein-Apheresis \u2013 S. Steiner (Vienna)<\/i><\/b><\/div>\n<div><\/div>\n<div>The lipoprotein-apheresis is a safe and effective therapy for the treatment of patients with homozygous or therapy refractory heterozygous familial hyperlipidaemia, elevated LP (a), intolerance of all lipid-lowering drug therapies and progressive atherosclerosis.<\/div>\n<div><\/div>\n<div>Various therapy systems achieve a comparable reduction of LDL cholesterol and LP (a) of 70-80%.<\/div>\n<div><\/div>\n<div>Intensive multi-disciplinary care of the patients, including regular monitoring of the course in specialized centres, is necessary and a prerequisite for successful treatment.<\/div>\n<p>&nbsp;<\/p>\n<hr \/>\n<div><b><i>Rheumatology\u2013 G. Stummvoll (Vienna)<\/i><\/b><\/div>\n<div><\/div>\n<div><b>IAS in heavy, therapy refractory SLE<\/b><\/div>\n<div><\/div>\n<div>Antibodies have a direct and indirkt (via immune complex) pathogenic role in SLE.<\/div>\n<div>IAS at SLE in<\/div>\n<div><\/div>\n<div>\u2022 In therapy refractory cases (Cyclophosphamidversager, MMF failure)<\/div>\n<div><\/div>\n<div>\u2022 If Cyc or MMF is contraindicated<\/div>\n<p>&nbsp;<\/p>\n<div><strong>IAS at SLE is feasible:<\/strong><\/div>\n<div><\/div>\n<div>Infections are dependent on disease activity and KO medication (cyc, steroids), IAS makes no difference. Ref. <b>Stummvoll GH, Vienna. Klin. Wochenschr., 2004<\/b><\/div>\n<div><\/div>\n<div>E. G:: IAS successfully in patients with lupus-GN IV and Gleichzeitiber tuberculosis. Ref. S. Narrow service, Am J Kid dis2002<\/div>\n<p>&nbsp;<\/p>\n<div><strong>IAS at SLE is effective<\/strong><\/div>\n<p>&nbsp;<\/p>\n<div>\u2022 Fast effect &#8220;short-term&#8221;: reduction of global disease activity, anti-dsDNA mirror and within 3 months also proteinuria. Ref. GH Stummvoll, annrheumdis2005<\/div>\n<div><\/div>\n<div>\u2022 High rate of remissions<\/div>\n<div><\/div>\n<div>\u2022 Prolonged IAS (&gt; 1yr) feasible, stabilizes activity parameters, reduces proteinuria further. Ref. G.H. Stummvoll, NDephrologyDialysis and Transplantation 2011<\/div>\n<p>&nbsp;<\/p>\n<p><strong>Methods<\/strong><\/p>\n<div>Wiener apheresis Einheit, inner med. 3\/Nephrology, Meduniwien<\/div>\n<div><\/div>\n<div>3 high-affinity adsorber are in use with different ligands are in use:<\/div>\n<div><\/div>\n<div><b>\u2013 Sheep IG<\/b> (Therasorb \u00ae)<b>, Protein A <\/b>(Immunosorba \u00ae), <b>Synthetic peptide GAM<\/b> (Globaffin \u00ae)<\/div>\n<div><b>\u00e0 All effective if IG completely removed (in maintenance therapy)<\/b><\/div>\n<div><b>Ref Biesenbach,&#8230;, Stummvoll, Artherosclerosis soup 2009<\/b><\/div>\n<p>&nbsp;<\/p>\n<p><strong>Future?<\/strong><\/p>\n<div>\u2022 IAS currently as a Ultima ratio<\/div>\n<div><\/div>\n<div>\u2013 Used earlier?<\/div>\n<div><\/div>\n<div>\u2022 Prospective study?<\/div>\n<div><\/div>\n<div>\u2022 Which Adsober type is better?<\/div>\n<div><\/div>\n<div><\/div>\n<div>Based on the data and the pathogenetically implied meaning<\/div>\n<p>&nbsp;<\/p>","protected":false},"excerpt":{"rendered":"<p>25 &#8211; 27 September, 2014 Salzburg Congress, Austria &nbsp; Lipoprotein-Apheresis \u2013 S. Steiner (Vienna) The lipoprotein-apheresis is a safe and effective therapy for the treatment of patients with homozygous or therapy refractory heterozygous familial hyperlipidaemia, elevated LP (a), intolerance of all lipid-lowering drug therapies and progressive atherosclerosis. Various therapy systems achieve a comparable reduction of [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_mc_calendar":[],"footnotes":""},"_links":{"self":[{"href":"https:\/\/www.austrian-apheresis-association.at\/aaa\/en\/wp-json\/wp\/v2\/pages\/174"}],"collection":[{"href":"https:\/\/www.austrian-apheresis-association.at\/aaa\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.austrian-apheresis-association.at\/aaa\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.austrian-apheresis-association.at\/aaa\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.austrian-apheresis-association.at\/aaa\/en\/wp-json\/wp\/v2\/comments?post=174"}],"version-history":[{"count":10,"href":"https:\/\/www.austrian-apheresis-association.at\/aaa\/en\/wp-json\/wp\/v2\/pages\/174\/revisions"}],"predecessor-version":[{"id":1003,"href":"https:\/\/www.austrian-apheresis-association.at\/aaa\/en\/wp-json\/wp\/v2\/pages\/174\/revisions\/1003"}],"wp:attachment":[{"href":"https:\/\/www.austrian-apheresis-association.at\/aaa\/en\/wp-json\/wp\/v2\/media?parent=174"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}